Introduction {#s1}
============

Bevacizumab (Avastin; Genentech, South San Francisco, CA, USA) is a humanized monoclonal antibody to the vascular endothelial growth factor (VEGF). It is currently indicated for non-small cell lung cancer, renal cell carcinoma, breast cancer and ovarian cancer \[[@SFV139C1]\]. It was recently approved for recurrent high-grade gliomas, particularly glioblastoma multiforme \[[@SFV139C1]--[@SFV139C6]\]. The safety profile is well established and there have been several studies confirming its efficacy as well as tolerability in elderly patients with advanced malignancies \[[@SFV139C7]\].

Bevacizumab inhibits angiogenesis by direct binding of VEGF and disruption of VEGF receptor signaling. VEGF receptors are expressed predominantly on vascular endothelial cells. Other sites with increased expression are glomerular podocytes where VEGF receptors cover the glomerular basement membrane \[[@SFV139C8], [@SFV139C9]\]. Pathological VEGF signaling has been implicated in proteinuria associated with pre-eclampsia, diabetic nephropathy and treatment with mammalian target of rapamycin (m-TOR) inhibitors such as sirolimus and everolimus \[[@SFV139C10], [@SFV139C11]\].

Proteinuria, hypertension and thrombotic microangiopathy (TMA) have been increasingly reported as adverse effects from the administration of bevacizumab and other antiangiogenesis inhibitors \[[@SFV139C5], [@SFV139C12]\]. Acute kidney injury (AKI) due to TMA from this class of agents has been well described \[[@SFV139C13]\]. This lesion is associated with severe renal failure and is usually treated by withdrawal of the VEGF inhibitor rather than plasmapheresis \[[@SFV139C14]\]. The transient nature of proteinuria and self-limiting nature of avastin-induced disease practically means that proteinuria resolves only by withholding the offending agent. Biopsies are often only obtained for rare cases of glomerular disease resulting in ongoing proteinuria. New expert opinions are being formed as to when biopsies in anti-VEGF renal disease should be obtained \[[@SFV139C15]\]. Minimal change disease (MCD) in association with bevacizumab use has not been described *de novo* in adults with systemic anti-VEGF therapy. Previous case reports by and Pérez-Valdivia *et al*. \[[@SFV139C16]\] and Soto *et al*. \[[@SFV139C17]\] reported relapses of MCD after intravitreal administrations of bevacizumab, and both were treated with systemic steroids. Another case report from Japan noted persistent proteinuria with long-term use of systemic bevacizumab and described a complex glomerulopathy with finding of double contours without evidence of antibody staining, which attenuated with losartan use. In this case, however, the renal biopsy pattern was not consistent with MCD as seen here \[[@SFV139C18]\].

Case report {#s2}
===========

A 72-year-old Caucasian man diagnosed with a World Health Organization (WHO) Grade 3 anaplastic astrocytoma presented to Cedars Sinai Medical Center with AKI and 3+ proteinuria on urinalysis 4 weeks after the initiation of bevacizumab. He was initially diagnosed with glioblastoma multiforme in January 2012, after presenting with a generalized tonic--clonic seizure. He received radiotherapy and chemotherapy with dose-dense temozolomide in April 2012, with a good response.

On 7 August 2012, the patient began a combination of temozolomide and bevacizumab, with scheduled bevacizumab every 2 weeks. Prior to initiating therapy he was noted to have type 2 diabetes mellitus without evidence of either diabetic retinopathy or high-grade proteinuria (he had microalbuminuria). Four weeks later, before his third treatment, he was found to have 3+ proteinuria on urinalysis and a mildly elevated serum creatinine of 88.4 μmol/L \[1 mg/dL; baseline 70.72 μmol/L (0.8 mg/dL)\]. Bevacizimab was held. The urine protein-to-creatinine ratio was markedly elevated (17.89 g of protein of creatinine). Two weeks later, he returned to his neuro-oncologist with 4+ proteinuria, hypertension, anasarca, severe hypoalbuminemia with serum albumin 231.84 μmol/L (1.6 g/dL) and worsening AKI with a serum creatinine of 123.76 μmol/L (1.4 mg/dL). Repeat urine protein-to-creatinine ratio was 19.51 g/g of creatinine (Figure [1](#SFV139F1){ref-type="fig"} ). Fig. 1.Trends of serum creatinine, urinalysis proteinuria/albuminuria and urine protein-to-creatinine ratio. (**A**) Trend of serum creatinine versus time (serum creatinine in mg/dL). (**B**) Trend of urinalysis proteinuria versus time (1+ to 4+ proteinuria). (**C**) Trend of urine protein-to-creatinine ratio (g protein/g creatinine). Arrows: temporal representation of two avastin administrations timed 7 and 21 August 2012.

He was admitted for further renal evaluation. During that admission he developed progressive nonoliguric AKI with a peak creatinine of 424.32 μmol/L (4.8 mg/dL). Obstructive uropathy, acute interstitial nephritis (AIN) and acute tubular necrosis (ATN) were considered unlikely causes of AKI. Glomerulonephritis was suspected given the patient\'s high-grade proteinuria. Bevacizumab was thought to be the etiology of proteinuria and AKI, although the clinical presentation did not conform to the classic pattern of bevacizumab-induced TMA. A computed tomography (CT)--guided renal biopsy was performed to investigate the etiology of nephrotic syndrome and AKI.

The kidney biopsy included portions of cortex with 17 glomeruli, 4 of which were completely sclerosed. Importantly, there was no evidence of focal and segmental sclerosis (FSGS) on light microscopy, and renal pathology confirmed that the findings did not suggest FSGS. Most of the remaining glomeruli were structurally normal with patent capillary lumina and single contoured capillary walls. Few fresh fibrin thrombi were in some capillary lumina of three glomeruli. Cells of many proximal tubules were irregular and flattened and some lacked brush border staining. There was mild tubular atrophy with interstitial fibrosis. Other light microscopic changes were not evident. Immunofluorescence was negative in all glomeruli in that portion of the specimen \[[@SFV139C3]\].

Electron microscopy disclosed complete effacement of podocyte foot processes, lack of electron dense deposits and no evidence of luminal or mural fibrin in the capillaries (Figure [2](#SFV139F2){ref-type="fig"}). Fig. 2.Biopsy specimens showing bevacizumab-induced MCD and fibrin thrombi. (**A**) Complete podocyte foot process effacement seen on electron microscopy. (**B**) Normal glomerulus (periodic acid-Schiff stain).

AKI and proteinuria persisted for \>2 weeks after the withdrawal of bevacizumab. Deterioration of renal function resulted in worsening volume overload and uremia. Renal replacement therapy was considered. After the biopsy results, 1 mg/kg oral prednisone was started to treat the MCD.

Within 4 days after starting high-dose steroids, the patient\'s serum creatinine improved and renal replacement therapy was not needed. Proteinuria improved more gradually and decreased from 19 to 11 g in \<1 week. It decreased further to \<1 g after 6 weeks of steroid and angiotensin-converting enzyme inhibitor therapy, and subsequently resolved after nearly 2 months of therapy for MCD (Figure [1](#SFV139F1){ref-type="fig"}).

Discussion {#s3}
==========

To our knowledge, this is the first reported case of renal failure and *de novo* MCD associated temporally with systemic bevacizumab use. Previous cases noted above (Pérez-Valdivia *et al*. \[[@SFV139C16]\] and Soto *et al*. \[[@SFV139C17]\]) showed a relapse of MCD after intravitreal bevacizumab administration and Haruhara *et al*. \[[@SFV139C18]\] showed an atypical light microscopic pattern of double contouring without evidence of immune complex deposition. Renal failure, hypertension and transient proteinuria occur in up to 18% of patients receiving bevacizimab, although sustained proteinuria and renal failure are both rare features of bevacizimab nephrotoxicity \[[@SFV139C19]\]. It is important to recognize MCD as an adverse effect of therapy with bevacizimab since this patient did not respond to cessation of therapy alone and required high-dose steroid therapy for restoration of renal functions.

There have been other glomerulopathies associated with treatments of cancer with anti-VEGF and anti-epidermal growth factor (EGF) biologic agents. Bevacizimab has been associated with cryoglobulinemic glomerulonephritis, collapsing glomerulonephritis, membranoproliferative glomerulonephritis (MPGN) and the more commonly reported lesions of TMA \[[@SFV139C19]\]. Trastuzumab, which is a related antiendothelial growth factor receptor monoclonal antibody, has been linked to one case of MCD \[[@SFV139C19]\]. Sorafenib, axitinib, gefitinib, imatinib, sunitinib and small molecule tyrosine kinase inhibitors, which target signaling proteins downstream of the VEGF receptor, have been associated with focal segmental glomerulosclerosis (FSGS), ischemic glomerulonephritis, ATN and AIN (see Table [1](#SFV139TB1){ref-type="table"}) \[[@SFV139C15]--[@SFV139C30]\]. Sorafenib has recently been linked with MCD as well \[[@SFV139C31]\]. In the case of Haruhara *et al*. \[[@SFV139C19]\] mentioned previously, a complex glomerulopathy was noted that responded to renin--angiotensin systemic blockade with losartan. Table 1.Cases reports of glomerulopathies and kidney injury due to VEGF and EGF receptor inhibitionDrugPathologyCitationAnti-VEGF monoclonal antibodies (IV, intravitreal) adapted from Izzedine *et al*. \[[@SFV139C19]\] and updated Bevacizumab-IVMCDOur case (Hanna *et al*.) reported 2015 Bevacizumab-IVGlomerulopathy with double contouring, nonimmuneHaruhara *et al*. \[[@SFV139C18]\] Bevacizumab-intravitrealMCDSoto *et al*. \[[@SFV139C17]\] Bevacizumab-intravitrealMCDPerez-Valdivia *et al*. \[[@SFV139C16]\] Bevacizumab-IVCollapsing glomerulonephritisJohnson *et al*. \[[@SFV139C24]\] (compiled in Izzedine *et al*.) Bevacizumab-IVMPGNMiller *et al*. \[[@SFV139C27]\] (compiled in Izzedine *et al*.) Bevacizumab-IVThrombotic microangiopathyMany reviews including Eremina *et al*. \[[@SFV139C21]\] VEGF-trap/Aflibercept-route unknownCrescentic glomerulonephritisFrom unpublished data per Izzedine *et al*.Anti-EGF monoclonal antibodies adapted from Izzedine *et al*. \[[@SFV139C19]\] Trastuzumab-IVMCDVidal \[[@SFV139C29]\] (compiled in Izzedine *et al*.) Trastuzumab-IVFocal and segmental glomerulosclerosisVidal \[[@SFV139C29]\] (compiled in Izzedine *et al*.) Trastuzumab-IVFibrillary glomerulonephritisVidal \[[@SFV139C29]\] (compiled in Izzedine *et al*.)Tyrosine kinase inhibitors (PO) downstream from VEGF and EGF signaling pathways adapted from Izzedine *et al*. \[[@SFV139C19]\] Axitinib-POCollapsing glomerulonephritisFrom unpublished data per Izzedine *et al*. Gefitinib-POMinimal change nephropathyKumasuka *et al*. \[[@SFV139C26]\] (compiled in Izzedine *et al*.) Gefitinib-POATNWan and Yao \[[@SFV139C30]\] (compiled in Izzedine *et al*.) Imatinib-POThrombotic microangiopathyAl aly *et al*. \[[@SFV139C20]\] (compiled in Izzedine *et al*.) Imatinib-POATNPou *et al*. \[[@SFV139C28]\] (compiled in Izzedine *et al*.) Imatinib-POATNKitiyakara and Atichartakarn \[[@SFV139C25]\] (compiled in Izzedine *et al*.) Sorafenib-POAINFrom unpublished data per Izzedine *et al*. Sunitinib-POIschemic glomerulonephritisFrom unpublished data per Izzedine *et al*.

There are many reported glomerulopathies that have been reported chronologically and were first compiled by Izzedine *et al*. \[[@SFV139C19]\] in an article published in the *American Journal of Kidney Disease* \[[@SFV139C15]--[@SFV139C30]\]. A table was compiled to show all the reported cases of glomerulopathies noted in cases of anti-EGF and anti-VEGF therapies and expanded to include the new cases mentioned above \[[@SFV139C16]--[@SFV139C18]\]. The table\'s focus is on expanding the new case reports of glomerular disease specific to bevacizumab, while other references to diseases due to anti-EGF therapies and tyrosine kinase inhibitors are adapted from Izzedine *et al*. \[[@SFV139C19]\] (see Table [1](#SFV139TB1){ref-type="table"}).

It is striking that while these angiogenesis inhibitors act on the same pathway, they can cause renal failure by various pathophysiologic mechanisms. These adverse events are rare, but compounded together, they form a growing understanding of how these drugs affect renal molecular biology and physiology.

It is important to record the clinical course we observed in this patient, as this is the first *de novo* case of MCD linked to systemic bevacizimab. Usually, the proteinuria linked to this agent is transient and may resolve with withdrawal of the agent. The underlying pathologic diagnosis may be important in cases of persistent proteinuria.

Although rare, drug-induced glomerulopathies can be progressive and lead to end-stage renal disease unless diagnosed quickly and appropriately treated. In this patient, proteinuria and renal failure progressed despite stopping the offending agent and only improved after initiation of high-dose steroids. This suggests a role for high-dose steroids in patients with MCD associated with bevacizumab use. This diagnosis and associated treatment should be considered in patients with bevacizumab-associated nephrotic syndrome. Other case reports described above mention differing pathological patterns found on biopsy after development of glomerular proteinuria and AKI in conjunction with bevacizumab and other anti-VEGF and anti-EGF therapies \[[@SFV139C16]--[@SFV139C19]\]. In one of these cases, angiotensin receptor blockade resulted in attenuation of proteinuria due to bevacizumab therapy. The lesion in this case was associated with a double contour nonimmune glomerulopathy pattern on renal biopsy. Thus, it is important to distinguish that steroid therapy has only been shown to be efficacious in the literature with MCD pattern glomerular injury after anti-VEGF therapy with systemic or intravitreal bevacizumab \[[@SFV139C16]--[@SFV139C18]\].
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